§
Luxuse
Patent Intelligence
Sign In
← Back to Patent Explorer
EP0073953A2 Expired / Lapsed EP ⏱️ 0.0 years remaining

Monoclonal antibodies to cell surface antigens of human renal cancer

Assignee: Memorial Sloan Kettering Cancer Center
•
Filing: 1982-08-13
•
Granted: —
•
Expires: 2002-08-13
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Seventeen monoclonal antibodies derived from fusions with spleen cells of mice immunized with established culture lines of renal cancers identified nine cell surface antigenic systems. Six of the systems (gp 160, S 25 , gp120r, gp120nr, gp115, and V,) represents antigens not previously described. The most restricted of the newly described antigens are gp160, S 25 , and gp1120r. These determinants are found only on cells or renal origin, both normal and malignant, and represent differentiation antigens of human kidney. These systems can be used to characterize and study the nature of renal cancer. Thus, comparison of the S 25 and the gp160 phenotypes of different renal cancer cell lines and cultures of normal kidney clearly distinguish these two systems.

Inventors

  • 👤 Lloyd J. Old
  • 👤 Connie L. Finstad
  • 👤 Kenneth O. Lloyd
  • 👤 Donna Morrissey
  • 👤 Herbert F. Oettgen
  • 👤 Shun-Ichiro Ogata
  • 👤 Willet F. Whitmore
  • 👤 Ryuzo Ueda
  • 👤 Jerzy Szkudlarek

Bibliographic Details

Application Number —
Jurisdiction EP
Data Source google_patents
Last Synchronized 2026-11-05 18:03
CPC Classifications
C; C07; C07K; C07K16/00; C07K16/18; C07K16/28; C07K16/30; C07K16/3038; Y; Y10; Y10S; Y10S435/00; Y10S435/8215; Y10S435/948; Y10S530/00; Y10S530/808; Y10S530/809; Y10S530/863; Y10S530/864

Claims Analysis

Total Claims: 15
Claim 1
Independent Claim 5 words
Monoclonal antibody recognizing renal cells.
Claim 2
Dependent Claim 5 words
Monoclonal antibody recognizing renal cells.
Claim 3
Dependent Claim 11 words
Monoclonal antibody of claim 1 wherein said renal cells are malignant.
Claim 4
Dependent Claim 9 words
Monoclonal antibody of claim 1 recognizing gp160 antigenic system.
Claim 5
Dependent Claim 10 words
Monoclonal antibody of claim 1 recognizing S 25 antigenic system.
Claim 6
Dependent Claim 11 words
Monoclonal antibody of claim 1 recognizing gp120r or gp120nr antigenic system.
Claim 7
Dependent Claim 9 words
Monoclonal antibody of claim 1 recognizing gp115 antigenic system.
Claim 8
Dependent Claim 9 words
Monoclonal antibody of claim 1 recognizing V. antigenic system.
Claim 9
Dependent Claim 9 words
Monoclonal antibody of claim 1 recognizing HLA heavy chain.
Claim 10
Dependent Claim 12 words
Monoclonal antibody of claim 1 recognizing A or B blood group antigens.
Claim 11
Dependent Claim 16 words
Antibody producing hybridoma cell line characterized by the production of the antibodies claimed in Claim 1.
Claim 12
Dependent Claim 27 words
Antibody producing hybridoma cell line formed by fusing a myeloma derived cell strain and splenocytes derived from BALB/c mice immunized with established culture lines of renal cancer.
Claim 13
Dependent Claim 27 words
Antibody producing hybridoma cell line formed by fusing a myeloma derived cell strain and splenocytes derived from BALB/c mice immunized with established culture lines of renal cancer.
Claim 14
Dependent Claim 30 words
Method of forming an antibody producing hybridoma cell line by fusing a myeloma derived cell strain with splenocytes derived from BALB/c mice immunized with established culture lines of renal cancer.
Claim 15
Dependent Claim 30 words
Method of forming an antibody producing hybridoma cell line by fusing a myeloma derived cell strain with splenocytes derived from BALB/c mice immunized with established culture lines of renal cancer.

References Cited (Backward Citations)

No citation records indexed.

USPTO Annuity & Maintenance Windows

Maintenance schedule is calculated for granted US utility patents.

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag